NasdaqCM:PSTV

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and manufacture of treatments for cancer and other diseases. More Details


Snowflake Analysis

Adequate balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Plus Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PSTV is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: PSTV's weekly volatility has decreased from 16% to 10% over the past year.


Market Performance


7 Day Return

-0.9%

PSTV

2.8%

US Biotechs

1.5%

US Market


1 Year Return

5.0%

PSTV

27.3%

US Biotechs

22.3%

US Market

Return vs Industry: PSTV underperformed the US Biotechs industry which returned 27.2% over the past year.

Return vs Market: PSTV underperformed the US Market which returned 22.1% over the past year.


Shareholder returns

PSTVIndustryMarket
7 Day-0.9%2.8%1.5%
30 Day-3.6%7.8%8.8%
90 Day-19.4%17.5%10.8%
1 Year5.0%5.0%29.5%27.3%25.1%22.3%
3 Year-98.4%-98.4%26.5%20.1%49.5%39.6%
5 Year-99.9%-99.9%21.0%12.7%105.8%83.3%

Long-Term Price Volatility Vs. Market

How volatile is Plus Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Plus Therapeutics undervalued compared to its fair value and its price relative to the market?

3.71x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PSTV's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PSTV's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PSTV is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: PSTV is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PSTV's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PSTV is overvalued based on its PB Ratio (3.7x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Plus Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-41.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PSTV is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PSTV is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PSTV is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PSTV's revenue is expected to decline over the next 3 years (-64.2% per year).

High Growth Revenue: PSTV's revenue is forecast to decline over the next 3 years (-64.2% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PSTV's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Plus Therapeutics performed over the past 5 years?

23.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PSTV is currently unprofitable.

Growing Profit Margin: PSTV is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PSTV is unprofitable, but has reduced losses over the past 5 years at a rate of 23.7% per year.

Accelerating Growth: Unable to compare PSTV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PSTV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.8%).


Return on Equity

High ROE: PSTV has a negative Return on Equity (-142.46%), as it is currently unprofitable.


Next Steps

Financial Health

How is Plus Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: PSTV's short term assets ($8.6M) exceed its short term liabilities ($8.4M).

Long Term Liabilities: PSTV's short term assets ($8.6M) exceed its long term liabilities ($628.0K).


Debt to Equity History and Analysis

Debt Level: PSTV's debt to equity ratio (235.8%) is considered high.

Reducing Debt: PSTV's debt to equity ratio has reduced from 318.6% to 235.8% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PSTV has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PSTV has less than a year of cash runway if free cash flow continues to grow at historical rates of 24.5% each year.


Next Steps

Dividend

What is Plus Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PSTV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PSTV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PSTV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PSTV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PSTV's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.1yrs

Average management tenure


CEO

Marc Hedrick (57 yo)

6.67yrs

Tenure

US$867,428

Compensation

Dr. Marc H. Hedrick, M.D. has been the President of Plus Therapeutics, Inc. (also known as Cytori Therapeutics, Inc. and Macropore Biosurgery Inc.) since May 2004 and has been its Chief Executive Officer s...


CEO Compensation Analysis

Compensation vs Market: Marc's total compensation ($USD867.43K) is above average for companies of similar size in the US market ($USD560.00K).

Compensation vs Earnings: Marc's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Marc Hedrick
President6.67yrsUS$867.43k0.24%
$ 24.1k
Andrew Sims
VP of Finance & CFO0.83yrno datano data
Desiree Smith
Corporate Controller1.08yrsno datano data
John Fraser
Chief Scientistno datano datano data
Russ Havranek
Vice President of Corporate Strategyno datano datano data
Gary Titus
1.42yrsno datano data
Gregory Stein
Senior Vice President of Clinical Development0.67yrno datano data

1.1yrs

Average Tenure

57yo

Average Age

Experienced Management: PSTV's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Marc Hedrick
President6.67yrsUS$867.43k0.24%
$ 24.1k
Robert Lenk
Independent Director0.67yrno data0.063%
$ 6.4k
Gregory Petersen
Independent Director0.83yrno data0.42%
$ 42.4k
Richard Hawkins
Independent Chairman of the Board2.92yrsUS$52.50k0.00036%
$ 36.5
Howard Clowes
Independent Director0.67yrno datano data
Andrew Brenner
Member of Scientific Advisory Board0.083yrno datano data
Nicholas Butowski
Member of Clinical Advisory Board0.17yrno datano data
An van Es-Johansson
Independent Director0.92yrno datano data
Russell Lonser
Member of Clinical Advisory Board0.17yrno datano data
Alireza Mohammadi
Member of Clinical Advisory Board0.17yrno datano data
Michael Vogelbaum
Member of Clinical Advisory Board0.17yrno datano data
Manish Aghi
Member of Clinical Advisory Board0.17yrno datano data

0.4yrs

Average Tenure

63yo

Average Age

Experienced Board: PSTV's board of directors are not considered experienced ( 0.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PSTV insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.8%.


Top Shareholders

Company Information

Plus Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Plus Therapeutics, Inc.
  • Ticker: PSTV
  • Exchange: NasdaqCM
  • Founded: 1996
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$10.133m
  • Shares outstanding: 4.78m
  • Website: https://www.plustherapeutics.com

Number of Employees


Location

  • Plus Therapeutics, Inc.
  • 4200 Marathon Boulevard
  • Suite 200
  • Austin
  • Texas
  • 78756
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XMPADB (Deutsche Boerse AG)YesCommon StockDEEURAug 2000
PSTVNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDAug 2000

Biography

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and manufacture of treatments for cancer and other diseases. Its lead product candidate is DocePLUS,...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/06 00:43
End of Day Share Price2020/12/04 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.